Halozyme Therapeutics Inc HALO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Halozyme Announces Appointment of Jim Daly to its Board of Directors
-
Halozyme Therapeutics, Inc. Announces Pricing of Upsized Private Offering of $1.3 Billion of Convertible Senior Notes due 2033
-
Halozyme Therapeutics, Inc. Announces Proposed Offering of $1.05 Billion of Convertible Senior Notes due 2033
-
Halozyme to Participate at Upcoming Investor Conferences
-
Halozyme Appoints Dannielle Appelhans to its Board of Directors
-
HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
-
Halozyme to Report Second Quarter 2026 Financial and Operating Results
-
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
Trading Information
- Previous Close Price
- $106.94
- Day Range
- $106.65–109.99
- 52-Week Range
- $61.23–116.85
- Bid/Ask
- $105.46 / $110.00
- Shares Outstanding
- 113.50M
- Market Cap
- $12.47B
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- 19.95
- Price/Sales
- 7.86
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 3.06%
Company Profile
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 423
- Website
- https://www.halozyme.com
Valuation
|
Metric
|
HALO
|
|---|---|
Price/Earnings (Normalized) | 19.95 |
Price/Book Value | 84.96 |
Price/Sales | 7.86 |
Price/Cash Flow | 13.67 |
Price/Earnings
HALO
Financial Strength
|
Metric
|
HALO
|
|---|---|
Quick Ratio | 1.99 |
Current Ratio | 2.71 |
Interest Coverage | 29.73 |
Quick Ratio
HALO
Profitability
|
Metric
|
HALO
|
|---|---|
Return on Assets (Normalized) | 29.07% |
Return on Equity (Normalized) | 280.50% |
Return on Invested Capital (Normalized) | 33.40% |
Return on Assets
HALO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^pm?Y? | LOCK|j<&>V | $128B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|<?hG^?x | LOCK|&!W%C | $76B | |||
| Moderna Inc
MRNA
| LOCK|bK&B<Zy | LOCK|?> | $75B | |||
| argenx SE ADR
ARGX
| LOCK|KtM%!v! | LOCK|XjD | $60B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|l><WVP | LOCK|^# | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&%k#?Y | LOCK|>^slw | $31B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|!<tx<&#? | LOCK|yWPM | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|<CksWZ | LOCK|y%g | $24B | |||
| Incyte Corp
INCY
| LOCK|ln@vYv | LOCK|T$? | $24B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|ZpCyg@> | LOCK|pmH | $15B |
United States